Abstracts for conferences can be downloaded by clicking on links

AACR: Washington, DC, April 17-21, 2010

  • Multicenter Pharmacokinecit Evaluation of ON 01910.Na, a novel broad-spectrum anticancer agent, in Phase I Single Agent Clinical Trials in Patients with Solid Tumors. Manoj Maniar, Sridhar Mani, Mohammed H Ghalib, Imran Chaudhary, John Roboz, Takao Ohnuma, Suresh Advani, Raghunadh Rao, D Doval, Manmohan Acharya, Edward ORourke, Francois Wilhelm, James F Holland and David Taft
  • ON 01910.Na, a clinical stage anticancer mitotic inhibitor, produces prolonged hyperphosphorylation of RanGAP1•SUMO1 as a potential mechanism of G2/M arrest and apoptosis Irina Oussenko, James F. Holland, E. Premkumar Reddy, Takao Ohnuma.
  • ON 01910.Na, a clinical trial stage multi-kinase inhibitor, induces apoptosis in chronic lymphocytic leukemia (CLL) cells through inhibition of PI3K/AKT and activation of the JNK pathway resulting in NOXA and BIM upregulation Patricia Perez-Galan, Colby Chapman, Xiameng Sun, Federica Gibellini, Poching Liu, Nalini Raghavachari and Adrian Wiestner
  • Proposed Pathway of Disposition of ON 01910.Na, a Novel Clinical Trial Stage Anti-Cancer Agent: Implication of Mrp2 in Biliary Excretion in the Isolated Perfused Rat Liver System. David Taft, Amy Chun, Chen Ren and Manoj Maniar.

    • ASH: New Orleans, December 5-8, 2009

    • The PI3K inhibitor ON 01910.Na Inhibits Critical Survival Pathways in the Tumor Microenvironment and Induces Apoptosis in CLL cells Through Induction of NOXA and BIM. Patricia Perez-Galan, Colby Chapman, Federica Gibellini, Poching Liu, Nalini Raghavachari and Adrian Wiestner.
    • Initial Evaluation of a 48-h Continuous Intravenous Infusion Weekly Regimen of ON 01910.Na in Advanced Myelodysplastic Syndrome (MDS) Azra Raza, MD, Naomi Galili, PhD, Muhammad Shahzad Ali, MD, Fahad Ali, MD, Alyssa Goodman, Samir Ahmed Qasim, MD and Francois Wilhelm, MD, Ph.D.
    • ON 01910.Na Suppresses Cyclin D1 Accumulation in Trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size Elaine M Sloand, MD, Matthew J. Olnes, MD, PhD, Naomi Galili, PhD, Aarthi Shenoy, MD, Loretta Pfannes, Francois Wilhelm, MD, Ph.D, Barbara Weinstein, Phillip Scheinberg, MD, Jerome E. Groopman, MD8 and Azra Raza
    • Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na,a Novel Clinical Trial Stage Compound D.M. Soper, Y.W. Huang, F. Wilhelm, S. Cosenza, E.P. Reddy, A. Cesano, P.L. Greenberg, W.J. Fantl

      • 2009

      • Radiation protection by a new chemical entity, Ex-RadTM: efficacy and mechanisms. Ghosh SP, Perkins MW, Hieber K, Kulkarni S, Kao TC, Reddy EP, Reddy MVR, Maniar M, Seed T and Kumar KS. Radiat Res 171(2): 173-9 (2009).
      • Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Reddy MVR, Rudek MA, Kulesza P, Donehower RC, Reddy EP and Hidalgo M. Oncogene 28(4): 610-8 (2009).
      • Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Prasad A, Park IW, Allen H, Zhang X, Reddy MV, Boominathan R, Reddy EP and Groopman JE. Oncogene 28(12):1518-28 (2009).
      • Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Chun AW, Cosenza SC, Taft DR and Maniar M. Cancer Chemother Pharmacol (On-Line First) (2009).

      AACR: Denver, April 18-22, 2009

      • ON 01910.Na, a novel clinical grade PLK-1 inhibitor, selectively induces apoptosis in human B-cell chronic lymphocytic leukemia. Chapman CM, Perez-Galan P & Wiestner A. Abstract 3654 (2009).
      • Identification of a dual JAK-2/BCR-ABL kinase inhibitor for treatment of myeloproliferative disorders. Jatiani SS, Cosenza SC, Pallela VR, Ha JH, Baker SJ, Reddy MVR & Reddy EP. Abstract 3717 (2009).
      • Modulation of Chk1, Chk2, p-Chk2 dimer and p-ATM in cancer cells treated with ON 01910.Na, a clinical stage mitotic inhibitor. Oussenko I, Holland JF, Reddy EP & Ohnuma T. Abstract 3866 (2009).
      • Novel Bcr-abl kinase inhibitors active against T315I imatinib resistant mutation: (Z)-3-benzylideneindolinones: structure activity relationship and biological evaluation. Reddy MVR, Cosenza SC, Billa VK, Pallela VR, Mallireddigari MR & Reddy EP. Abstract 3718 (2009).
      • Pathway-based comparison approach for the identification of responders to the mitotic modulator ON 01910.Na in head and neck cancer (HNC). Tan AC, Anderson R, Frederick B, Raben D & Jimeno A. Abstract 4702 (2009).

      2008

      • Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, Hidalgo M, Baker SD, & Donehower RC. J Clin Oncol 26(34):5504-10 (2008).
      • Celecoxib and a novel COX-2 inhibitor ON 09310 upregulate death receptor-5 expression via GADD153/CHOP. Q. He, X. Luo, W. Jin, Y. Huang, M.V.R Reddy, E.P. Reddy and M.S. Sheikh. Oncogene, 27, 2656-2660, (2008).
      • Design, Synthesis and Biological Evaluation of (E)-Styryl Benzyl sulfones as Novel Anticancer Agents. M.V. Ramana Reddy, Muralidhar R Mallireddigari, Stephen C Cosenza, Venkat R Pallela, Nabisa M Iqbal, Anthony D. Kang and E. Premkumar Reddy. J.Med. Chem. 51, 86-100, (2008).
      • Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. M.V. Ramana Reddy, Vinay K Billa, Venkat R Pallela, Muralidhar R Mallireddigari, Rengasamy Boominathan, Jerome L Gabriel and E. Premkumar Reddy. Bioorg. Med.Chem, 16, 3907-3916, (2008).

      ASH: San Francisco, December 2008

      • Suppression of Cyclin D 1 (CD1) by ON 01910.Na is associated with decreased survival of trisomy 8 myelodysplastic bone marrow: a potential targeted therapy for trisomy 8 MDS. Shenoy A, Pfannes L, Wilhelm F, Young NS, & Sloand EM. Abstract 1651 (2008).

      ASCO: Chicago, May-June 2008

      • Phase 1 study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer. J.M.Vainshtein, M.H.Ghalib, M.Kumar, I.Chaudhary, M.Maniar, D.R.Taft, S.Cosenza, E.P.Reddy, S.Goel, S.Mani.

      AACR: San Diego, April 2008

      • Design, synthesis and biological evaluation of novel, orally available tubulin depolymerizing (E) N-aryl-2-arylethenesulfonamide compounds. M V Ramana Reddy, Stephen C. Cosenza, Venkat R. Pallela, Srinivas R. Natala, Muralidhar R., Mallireddigari, Manoj Maniar, Nabissa M. Iqbal, E Premkumar Reddy. Fels Institute for Cancer Research, Philadelphia, PA, Onconova Therapeutics Inc, Newtown, PA.

      2007

      • Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. I-W. Park, M.V.R Reddy, EP Reddy and JE Groopman. Oncogene, 1-8 (2007)
      • Evaluation of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, and development of a cyclin-B1-based predictive assay in pancreatic cancer. A. Jimeno, A. Chan, X. Zhang, J. Wheelhouse, A. Solomon, S. C. Cosenza, M.V.R Reddy, M. Rudek, P. Kulesza, E. Reddy, M. Hidalgo. J. Clin. Oncol. 25, No.18S, 3569 (2007).
      • Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J. Li, M. Zhao, A. Jimeno, P. He, M.V. Ramana Reddy, M. Hidalgo, R. C. Donehower and M.A. Rudek. J. Chromatogr B. 856, 198-204, (2007).

      ASH: Atlanta, December 2007

      • Suppression of Cyclin D1 by on 01910.Na Is Associated with Decreased Survival of Trisomy 8 Myelodyplastic Bone Marrow Progenitors: A Potential Targetted Therapy. Elaine M.Sloand,1 Loretta Pfannes*,1 Ramana Reddy*,2 Premkumar Reddy*,2 Jerome S.Groopman,3 Neal S.Young*.1 'Hematalogy Branch, Divison of Intramural Research, National Heart Lung and Blood Institute, Bethesda, MD USA; 2 Onconova Therapeutics. Lawrenceville, NJ, USA; 3 Experimental Hematology, Harvard University, Boston, MA, USA.

      AACR: Los Angeles, April 2007

      • LB-7 Phase I study of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, in adult patients with solid tumors. Antonio Jimeno, Jing Li, M.V.Ramana Reddy, E.Premkumar Reddy, Manoj Maniar, Daniel A.Laheru, Wells A.Messersmith, Michelle A.Rudek, Sharyn D.Baker, Manuel Hidalgo, Ross C.Donehower, Johns Hopkins University, Baltimore, MD; Fels Institute for Caner Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA; Onconova Therapeutics, New Jersey, NJ.

      ASCO: Chicago, June 2007

      • Evaluation of ON 01910.Na, a novel modulator of polo-like kinase 1 (Plk1) pathway, and development of a cyclin-B1-based predictive assay in pancreatic cancer. Author(s): A. Jimeno, A. Chan, X. Zhang, J. Wheelhouse, A. Solomon, S. C. Cosenza, M. Reddy, M. Rudek, P. Kulesza, E. Reddy, M. Hidalgo.

      2006

      ASCO: Atlanta, June 2006:

      • Phase I Study of ON 01910.Na by 3-day continuous infusion (CI) in patients with advanced cancer. T Ohnuma, S.Y. Cho, J. Roboz, J. Jiang, D. Lehrer, L.R. Silverman, J.D. Schwartz, E.P. Reddy; Mount Sinai School of Medicine, New York, NY; Temple University, Philadelphia, PA.
      • Phase I Study of ON 01910.Na, a novel cell cycle inhibitor in adult patients with solid tumors. R.C. Donehower, A. Jimeno, J.Li, K. Galvin, F. Anthony, R. Reddy, W. Messersmity, D. Laheru, S.D. Baker; Johns Hopkins University, Baltimore, MD; Onconova Therapeutics, Lawrenceville, NJ; Fels Institute, Temple University Medical School, Philadelphia, PA.
      • Regression of pre-established intracranial tumor growth by ON 01910.Na, a selective anticancer agent currently in Phase I trials. Christopher S. Gondi, Neelima Kandhukuri, Niranjan Yanamandra, M.V. Ramana Reddy, E.P. Reddy and Jasti Rao: University of Illinois at Peoria. Presentation on June 4th, 2006.

      AACR: Washington, D.C., April 2006:

      • Cross-resistance to ON 01910.Na among Drug-resistant Human tumor cell lines. Adrian Preda, Takao Ohnuma, Jiang, James F. Holland, E. Premkumar Reddy. Mount Sinai School of Medicine, New York, NY, Temple University, Philadelphia, PA
      • Toxicology of a novel small molecule ON 01910.Na on Human Bone Marrow and Leukemic Cells In Vitro. gor Skidan1, Svetlana Zinzar1, M.V. Ramana Reddy2 and E.P. Reddy2, James F. Holland1, Lewis R. Silverman1. Mount Sinai School of Medicine, New York, NY and Fels Institute, Temple University, Philadelphia, PA.
      • Mass Spectrometry of Intact Complexes of Benzyl Styryl Sulfone ON 01910.Na with Albumin using Direct Serum Injection. John Roboz, Sool Yeon Cho, Takao Ohnuma, Jian-Dong Jiang, Yanling Wang, *Stanley Bell, **E. Premkumar Reddy, and James F. Holland. Dept. Medicine, Mount Sinai School of Medicine, New York, NY 10029, *Onconova Therapeutics, Inc., Lawrenceville, NJ 08648, **Fels Institute for Cancer Research, Temple University, Philadelphia, PA, 19140.

      2005

      • Design, synthesis, and biological evaluation of (E)- and (Z)-styryl-2-acetoxyphenyl sulfides and sulfones as cyclooxygenase-2 inhibitors. M.V. Ramana Reddy, M.R. Mallireddigari, V.R. Pallela. Padmavathi.V,R. Boominathan, S.C. bell and E. Premkumar Reddy, Bioorg. Med. Chem, 13, 1715-1723 (2005).
      • A non-ATP-competitive inhibitor of BCR_ABL overrides imatinib resistance. Kiran G, S.J. Baker, S.C. Cosenza, J. Premila, A.D. Kang, K.A. Robell, M.V. Ramana Reddy, and E.Premkumar Reddy. Proc. Natl. Acad. Sci. USA, 102, 1992-1997 (2005).
      • New Coumarin-3(N-Aryl) carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1. N.S. Reddy, K. Gumireddi, M.R. Mallireddigari, S.C. Cosenza, P. Venkatapuram, S.C. Bell, E. Premkumar Reddy and M.V. Ramana Reddy, Bioorg.Med.Chem, 13, 3141-3147, (2005).
      • ON 01910, a non-ATP competitive small molecule inhibitor of Plk1 is a potent anticancer agent. K. Gumireddi,, M.V. Ramana Reddy, S.C. Cosenza, R. Boominathan, S.J. Baker, N. Papathi, J. Jiang, J. Holland and E. Premkumar Reddy. Cancer Cell, 7. 275-286, 2005.
      • Sequential reduction and dehydration of phenacyl-(E)-styryl sulfones to asymmetrical (E,E)- bis(styryl)sulfones. M.Mallireddigari, V.R. Pallela, E. premkumar Reddy and M.V. Ramana Reddy. Synthesis, 3639-3643 (2005).

      2004

      • Solvent dependent dehydrating condensation of benzylsulfonyl acetic acids. Reddy, N.S; Reddy, E. Premkumar and M.V. Ramana Reddy. Synthetic Communications, 34, 2691-2695 (2004).
      • Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. N.S. Reddy; M.R.Mallireddigari; S. C. Cosenza; K. Gumireddy; S.C. Bell; E. Premkumar Reddy, M.V. Ramana Reddy. Bioorg. Med. Chem. Lett. 14, 4093-4097 (2004).